33 employees
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
2017
$61M
from 4 investors over 4 rounds
Anjarium Biosciences raised $61M on September 15, 2021
Investors: Gimv, Omega Funds, Abingworth and Surveyor Capital